From: Association between statin therapy and outcomes in critically ill patients: a nested cohort study
 | Statin n = 107 | Non-statin n = 656 | Adjusted odds ratio (aOR)a | 95% confidence interval | P-value |
---|---|---|---|---|---|
Hospital mortality, no. (%) | 42/107 (39.3) | 200/656 (30.5) | 0.60 | (0.36 - 0.99) | 0.05 |
Stratified by age, no. (%) | Â | Â | Â | Â | Â |
   ≤ 58 yrs | 6/14 (42.9) | 62/374 (16.6) | 0.73 | (0.19 - 2.81) | 0.64 |
   > 58 yrs | 36/93 (38.7) | 138/282 (49.0) | 0.58 | (0.35 - 0.97) | 0.04 |
Gender, no. (%) | Â | Â | Â | Â | Â |
   Male | 21/63 (33.3) | 126/492 (25.6) | 0.56 | (0.29 - 1.08) | 0.08 |
   Female | 21/44 (47.7) | 74/164 (45.0) | 0.74 | (0.35 - 1.58) | 0.43 |
Admission category, no. (%) | Â | Â | Â | Â | Â |
   Postoperative | 1/4 (25.0) | 19/119 (16.0) | 0.75 | (0.04 - 14.82) | 0.85 |
   Nonoperative | 41/103 (40.0) | 181/537 (34.0) | 0.62 | (0.34 - 1.03) | 0.06 |
APACHE II, no. (%) | Â | Â | Â | Â | Â |
   APACHE≤ 22 | 8/33 (24.2) | 53/370 (14.3) | 0.77 | (0.27 - 2.21) | 0.63 |
   APACHE>22 | 34/74 (46.0) | 147/286 (51.4) | 0.54 | (0.31 - 0.96) | 0.03 |
SOFA, no. (%) | Â | Â | Â | Â | Â |
   ≤ 9 | 13/58 (22.4) | 63/346 (18.2) | 0.55 | (0.26 - 1.17) | 0.12 |
   > 9 | 29/49 (59.1) | 137/310 (44.2) | 0.73 | (0.36 - 1.48) | 0.38 |
History of diabetes, no. (%) | Â | Â | Â | Â | Â |
   Yes | 31/84 (37.0) | 106/209 (48.4) | 0.52 | (0.30 - 0.90) | 0.02 |
   No | 11/23 (47.8) | 94/437 (21.5) | 1.31 | (0.49 - 3.54) | 0.59 |
History of cardiovascular, no. (%) | Â | Â | Â | Â | Â |
   Yes | 23/54 (42.6) | 58/103 (56.3) | 0.59 | (0.3 - 1.2) | 0.13 |
   No | 19/53 (35.9) | 142/553 (25.7) | 0.52 | (0.27 - 1) | 0.06 |
Vasopressor therapy, no. (%) | Â | Â | Â | Â | Â |
   Yes | 31/73 (42.5) | 151/423 (35.7) | 0.53 | (0.29 - 0.97) | 0.04 |
   No | 23/34 (67.7) | 184/233 (79.0) | 0.92 | (0.37 - 2.25) | 0.84 |
Sepsis, no. (%) | Â | Â | Â | Â | Â |
   Yes | 12/28 (43.0) | 88/166 (53.0) | 0.64 | (0.26 - 1.58) | 0.33 |
   No | 30/79 (38.0) | 112/490 (23.0) | 0.72 | (0.41 - 1.28) | 0.26 |
Severe sepsis and septic shock no. (%) | Â | Â | Â | Â | Â |
   Yes | 14/26 (53.9) | 84/207 (40.6) | 0.22 | (0.07 - 0.66 | 0.007 |
   No | 28/81 (34.6) | 116/449 (25.7) | 0.78 | (0.45 - 1.37) | 0.38 |
Creatinine, no. (%) | Â | Â | Â | Â | Â |
   ≤ 100 μmol/L | 4/26 (15.4) | 70/351 (20.0) | 0.14 | (0.04 - 0.51) | 0.002 |
   > 100 μmol/L | 38/81 (47.0) | 130/305 (43.0) | 1.01 | (0.58 - 1.77) | 0.96 |
Platelets, no. (%) | Â | Â | Â | Â | Â |
   ≤ 180 | 12/25 (48.0) | 125/358 (35.0) | 0.62 | (0.24 - 1.62) | 0.33 |
   > 180 | 30/82 (36.6) | 75/298 (25.2) | 0.78 | (0.43 - 1.42) | 0.42 |
Bilirubin, no. (%) | Â | Â | Â | Â | Â |
   ≤ 16 μmol/L | 10/38 (26.3) | 54/212 (25.5) | 0.49 | (0.21 - 1.20) | 0.11 |
   > 16 μmol/L | 10/22 (45.5) | 73/223 (32.7) | 0.67 | (0.23 - 1.97) | 0.47 |
INR, no. (%) | Â | Â | Â | Â | Â |
   ≤1.2 | 20/59 (34.0) | 68/312 (21.8) | 0.79 | (0.40 - 1.58) | 0.51 |
   >1.2 | 22/48 (45.8) | 132/344 (38.4) | 0.53 | (0.26 - 1.09) | 0.09 |
GCS, no. (%) | Â | Â | Â | Â | Â |
   ≤ 9 | 19/50 (38.0) | 114/364 (31.3) | 0.34 | (0.17 - 0.71) | 0.004 |
   > 9 | 23/57 (40.4) | 86/292 (29.5) | 092 | (0.46 - 1.85) | 0.81 |
Length of stay, no. (%) | Â | Â | Â | Â | Â |
   ≤ 5 days | 4/39 (10.3) | 32/192 (16.7) | 0.40 | (0.13 - 1.28) | 0.12 |
   > 5 days | 38/68 (55.9) | 168/464 (36.2) | 0.63 | (0.34 - 1.19) | 0.16 |
Mechanical ventilation, no. (%) | Â | Â | Â | Â | Â |
   Yes | 40/92 (43.5) | 183/591 (31.0) | 0.66 | (0.34 - 1.10) | 0.11 |
   No | 2/15 (13.3) | 17/65 (26.2) | 0.75 | (0.09 - 6.43) | 0.79 |
Simvastatin, no. (%) | 12/44 (27.3) | 200/656 (30.5) | 0.37 | (0.17 - 0.81) | 0.01 |
Atorvastatin, no. (%) | 30/63 (47.6) | 200/656 (30.5) | 0.80 | (0.84 - 1.46) | 0.47 |